Neurological treatment developer Aptinyx has secured $70m in a Nan Fung-backed round to add to the $65m series A it closed in May 2016.
Nan Fung Life Sciences, a subsidiary of property development group Nan Fung, participated in a $70m series B round for US-based neurologic drug developer Aptinyx yesterday.
Bain Capital Life Sciences, a branch of private equity firm Bain Capital, led the round, in which Adage Capital, Partner Fund Management, Agent Capital, HBM Healthcare Investments and Rock Springs Capital participated as new investors.
New Leaf Venture Partners, Adams Street Partners, LVP Life Science Ventures, Frazier Healthcare Partners, Goudy Park Capital, Beecken Petty…
